CureVac NV (XTER:5CV)

€ 2.966 0.222 (8.09%) Market Cap: 682.36 Mil Enterprise Value: 167.57 Mil PE Ratio: 5.46 PB Ratio: 0.85 GF Score: 56/100

Q3 2024 CureVac NV Earnings Call Transcript
Nov 12, 2024

€2.61 (-0.69%)

Earnings
Q4 2023 CureVac NV Earnings Call Transcript
Apr 24, 2024

€2.27 (-4.70%)

Earnings
Q3 2023 CureVac NV Earnings Call Transcript
Nov 14, 2023

€5.35 (+6.79%)

Earnings
CureVac NV at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Q4 2022 CureVac NV Earnings Call Transcript
Apr 25, 2023

€6.95 (-5.18%)

Earnings
CureVac NV Annual Shareholders Meeting Transcript
Mar 28, 2023
CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs Transcript
Jan 06, 2023
Q3 2022 CureVac NV Earnings Call Transcript
Nov 16, 2022

€7.89 (+2.04%)

Earnings
CureVac NV Annual Shareholders Meeting Transcript
Jun 22, 2022
CureVac NV at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
CureVac NV at Jefferies Healthcare Conference Transcript
Jun 09, 2022
CureVac NV at Bank of America Healthcare Conference Transcript
May 10, 2022
Q4 2021 CureVac NV Earnings Call Transcript
Apr 28, 2022

€15.2 (-1.05%)

Earnings
Q3 2021 CureVac NV Earnings Call Transcript
Nov 19, 2021

€36.83 (+4.54%)

Earnings
CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript
Oct 12, 2021
CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript
Jul 01, 2021
CureVac NV Updates On Clinical Trial - Corporate Call Transcript
Jun 17, 2021
Q4 2020 CureVac NV Earnings Call Transcript
Apr 15, 2021

€89 (+3.91%)

Earnings
CureVac N.V. - Special Call Transcript
Feb 05, 2021

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript

Oct 12, 2021 / 01:00PM GMT

Release Date Price: €34.58 (-7.66%)

Transcript

Sarah Fakih

CureVac N.V. - VP Corporate Communications & IR

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President, Investor Relations and Corporate Communications at CureVac.

Please let me introduce today's speaker. On the call with me from CureVac are Franz-Werner Haas, the Chief Executive Officer of CureVac; Pierre Kemula, our Chief Financial Officer; and Klaus Edvardsen, Chief Development Officer of CureVac. From GSK, we are joined today by Rino Rappuoli, Head of Vaccines R&D.

Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.

Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's view as of today, Tuesday, October 12, 2021. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.